Top priorities when applying QbD to biosimilar production

biosimilar, QbD, quality by design, physiochemcial, preclinical

Where do your current and future priorities lie in the biosimilar quality-by-design process?

We posed this question to the industry and the results are in;

  • the top priority when companies are looking to apply QbD to their biosimilar production is physiochemical characterisation
  • a close second are biological characterisations
  • and closing off the top three are preclinical concerns

What are your top priorities when it comes to QbD?


Interested in reading more on this topic? Take a look here:

Survey Download: Top challenges and opportunities in Biosimilar development

Top drivers fuelling industries biosimilar engagement today

Top strategic considerations when entering the biosimilars market

For more updates on pharma, biotech and R&D, follow us on Twitter: @biopharmaevents or join our LinkedIn group: BioPharma- Networking for Pharmaceuticals, Biotech and R&D

Leave a Reply

Your email address will not be published. Required fields are marked *